Systemic inhibition ofde novopurine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intake
Authors: Myers Jacob W. , Park Woo Yong , Eddie Alexander M. , Shinde Abhijit B. , Prasad Praveena , Murphy Alexandria C. , Leonard Michael Z. , Pinette Julia A. , Rampy Jessica J. , Montufar Claudia , Shaikh Zayedali , Hickman Tara T. , Reynolds Garrett N. , Winn Nathan C. , Lantier Louise , Peck Sun H. , Coate Katie C. , Stein Roland W. , Carrasco Nancy , Calipari Erin S. , McReynolds Melanie R. , Zaganjor Elma 
Published: November 2024

Objective

Obesity is a major health concern, largely because it contributes to type 2 diabetes mellitus (T2DM), cardiovascular disease, and various malignancies. Increase in circulating amino acids and lipids, in part due to adipose dysfunction, have been shown to drive obesity-mediated diseases. Similarly, elevated purines and uric acid, a degradation product of purine metabolism, are found in the bloodstream and in adipose tissue. These metabolic changes are correlated with metabolic syndrome, but little is known about the physiological effects of targeting purine biosynthesis.

Methods

To determine the effects of purine biosynthesis on organismal health we treated mice with mizoribine, an inhibitor of inosine monophosphate dehydrogenase 1 and 2 (IMPDH1/2), key enzymes in this pathway. Mice were fed either a low-fat (LFD; 13.5% kcal from fat) or a high-fat (HFD; 60% kcal from fat) diet for 30 days during drug or vehicle treatment. We ascertained the effects of mizoribine on weight gain, body composition, food intake and absorption, energy expenditure, and overall metabolic health.

Results

Mizoribine treatment prevented mice on a HFD from gaining weight, but had no effect on mice on a LFD. Body composition analysis demonstrated that mizoribine significantly reduced fat mass but did not affect lean mass. Although mizoribine had no effect on lipid absorption, food intake was reduced. Furthermore, mizoribine treatment induced adaptive thermogenesis in skeletal muscle by upregulating sarcolipin, a regulator of muscle thermogenesis. While mizoribine-treated mice exhibited less adipose tissue than controls, we did not observe lipotoxicity. Rather, mizoribine-treated mice displayed improved glucose tolerance and reduced ectopic lipid accumulation.

Conclusions

Inhibiting purine biosynthesis prevents mice on a HFD from gaining weight, and improves their metabolic health, to a significant degree. We also demonstrated that the purine biosynthesis pathway plays a previously unknown role in skeletal muscle thermogenesis. A deeper mechanistic understanding of how purine biosynthesis promotes thermogenesis and decreases food intake may pave the way to new anti-obesity therapies. Crucially, given that many purine inhibitors have been FDA-approved for use in treating various conditions, our results indicate that they may benefit overweight or obese patients.

Highlights

A purine biosynthesis inhibitor, mizoribine, protects against diet-induced weight gain

Mizoribine prevents fat mass gain in high-fat diet-fed male mice

Mizoribine reduces food intake and increases thermogenesis

Mizoribine induces expression of sarcolipin, a regulator of thermogenesis

Mizoribine treatment reduces ectopic lipids and increases glucose tolerance